Bicara Therapeutics Inc. Common Stock
Symbol: BCAX (NASDAQ)
16.58
▲ (4.98%) 0.787
Company Description:
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Key Stats
- Today's Open: $15.69
- Today's High: $16.679
- Today's Low: $15.61
- Today's Volume: 223.82K
- Yesterday Close: $15.79
- Yesterday High: $15.83
- Yesterday Low: $13.59
- Yesterday Volume: 956.18K
- Last Min Volume: 757
- Last Min High: $16.607
- Last Min Low: $16.6
- Last Min VWAP: $16.60496
Company Profile
- Name: Bicara Therapeutics Inc. Common Stock
- Website: https://www.bicara.com
- Listed Date: 2024-09-13
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0002023658
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $861.55M
- Round Lot: 100
- Outstanding Shares: 54.56M
- Asset Type: CS
RECENT FILINGS FOR BCAX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-29 | 144 | View |
| 2025-09-17 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-31 | SCHEDULE 13G/A | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-07-17 | SCHEDULE 13G/A | View |
| 2025-06-18 | 4 | View |
| 2025-06-16 | 144 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-06 | 8-K | View |
Latest News on BCAX